<DOC>
	<DOC>NCT00960804</DOC>
	<brief_summary>Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves</brief_summary>
	<brief_title>Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients</brief_title>
	<detailed_description>This study was terminated on 11 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Patients must consent in writing to participate in the study. Patients must be willing to comply with study visit schedule and study requirements, including, for women of childbearing potential or male patients with female partners of childbearing potential, the use of 2 forms of birth control, one of which is a barrier method. Patients must have participated in the A4091026 study. Withdrawn from the A4091026 study for an adverse event or serious adverse event. Pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to be pregnant during the course of clinical study. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>OA</keyword>
</DOC>